Skip to content
SPC Logo

Alphosyl '2 in 1' Shampoo

Last Updated on eMC 02-Sep-2015 View changes  | Omega Pharma Ltd Contact details

1. Name of the medicinal product

Alphosyl '2 in 1' Shampoo

2. Qualitative and quantitative composition

Alcoholic extract of coal tar 5.00% w/w

For excipients see 6.1

3. Pharmaceutical form

Medicated Shampoo

4. Clinical particulars
4.1 Therapeutic indications

Coal tar shampoo is indicated for the treatment of scalp disorders including:

- Psoriasis

- Seborrhoeic dermatitis

- Eczema

- Pruritus and scalp associated with psoriasis, seborrhoeic dermatitis and eczema

- Itchy, oily scalp

Dandruff.

4.2 Posology and method of administration

Adults and children aged 12 years and older:

Alphosyl '2 in 1' Shampoo is for topical application to the scalp.

The hair should be wetted and sufficient Alphosyl '2 in 1' Shampoo applied to produce an abundant lather. The scalp and adjacent areas should be vigorously massaged with the fingertips. The hair should be then thoroughly rinsed and the procedure repeated. Taking both of these shampoo applications into consideration, the total leave on time for the shampoo should be 3 – 5 minutes.

Alphosyl '2 in 1' Shampoo should be used once or twice weekly for the treatment of scalp disorders. The normal duration of use is 4 weeks, after which the condition should improve. Longer duration of therapy should be continued under the supervision of a physician.

Children:

The safety and efficacy of Alphosyl '2 in 1' Shampoo in children under 12 years of age have not been established.

Coal tar preparations have been used in children for many years, but since there is very little documented clinical data in this patient population, Alphosyl '2 in 1' Shampoo should be used with caution in children and only on the recommendation of a doctor or pharmacist.

Elderly:

No dosage adjustment is necessary.

Renal Impairment:

No dosage adjustment is necessary.

Hepatic Impairment:

No dosage adjustment is necessary.

4.3 Contraindications

Known hypersensitivity to coal tar or to any of the excipients in the preparation.

The following conditions should not be treated with Alphosyl '2 in 1' Shampoo:

Infected open skin lesions

Sore or acute pustular psoriasis.

4.4 Special warnings and precautions for use

For cutaneous use only.

Coal tar preparations may cause irritancy; therefore contact with sensitive areas, such as broken or very inflamed skin, should be avoided.

If irritation develops, treatment should be discontinued.

Avoid contact with eyes. If contact occurs rinse eyes thoroughly with water.

Alphosyl '2 in 1' Shampoo can stain skin and clothes. Contact with clothes should be avoided. Skin stains will wear off after treatment is stopped.

In rare instances, temporary hair colour changes may occur.

As Alphosyl '2 in 1' Shampoo may cause increased sensitivity to sunlight, sunlamps should not be used and deliberate or prolonged exposure of the scalp to sunlight should be avoided or minimised.

Alphosyl '2 in 1' Shampoo should be used with caution if the patient is also taking drugs known to be photosensitisers (e.g. thiazides, tetreacyclines, fluoroquinolones, phenothiazines, sulphonamides) because of the increased possibility of augmented photosensitivity.

4.5 Interaction with other medicinal products and other forms of interaction

None known

4.6 Fertility, pregnancy and lactation

Fertility

There are no data on the effects of topical coal tar preparations on human fertility.

Pregnancy

There are limited data from the use of coal tar preparations in pregnant women.

Coal tar has been shown to be fetotoxic and teratogenic to the offspring of laboratory animals when administered topically, orally or by inhalation at high and maternally toxic doses (see Non-clinical Information).

Use of coal tar preparations during pregnancy should only be considered if the expected benefit to the mother outweighs the potential risk to the foetus.

The use of coal tar products should be avoided in the first trimester of pregnancy.

Lactation

The safe use of topical coal tar preparations during lactation has not been established.

It is not known whether the topical application of coal tar preparations could result in sufficient systemic absorption to produce detectable amounts in breast milk.

Use of coal tar preparations during lactation should only be considered if the expected benefit to the mother outweighs the potential risk to the infant.

If used during lactation, patients should be advised to ensure that any residual product is fully washed off the breast prior to breast-feeding in order to avoid accidental ingestion by the infant.

4.7 Effects on ability to drive and use machines

None known

4.8 Undesirable effects

Adverse drug reactions (ADRs) are listed below by the MedDRA system organ class and by frequency. Frequencies are defines as: very common (≥1/10), common (≥1/100 and <1/10) , uncommon (≥1/1,0000 and <1/100), rare (≥1/10,000 and <1/1,000) and very rare (<1/10,000), including isolated reports.

Post-marketing data

Immune system disorders

Rare: Hypersensitivity (including pruritus, angioedema, dyspnoea)

Eye disorders

Rare: Eye irritation

Skin and subcutaneous tissue disorders

Rare: Alopecia, dermatitis, hair colour changes, abnormal hair texture, photosensitivity reaction, skin irritation (including dry skin, erythema and skin burning sensation).

General disorders and administration site conditions

Rare: Application site hypersensitivity, application site pain, application site rash, localised oedema.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

4.9 Overdose

Symptoms and signs:

Topical coal tar overdose may increase the rate of skin irritation and photosensitivity. (See Adverse Reactions).

Treatment:

Management should be clinically indicated or as recommended by the national poisons centre, where available.

5. Pharmacological properties
5.1 Pharmacodynamic properties

ATC Code:

D05AA Tars

Mechanism of action

Coal tars suppress DNA synthesis in hyperplastic skin inhibiting mitotic activity protein synthesis and cell reproduction.

Coal tar

Coal tar decreases epidermal proliferation and dermal infiltration and thus promotes a return to normal keratinisation. Coal tar has anti-inflammatory, antibacterial, antipruritic, keratolytic, keratoplastic and vascoconstrictive effects.

5.2 Pharmacokinetic properties

In a study using a variety of coal tar preparations total urinary poly aromatic hydrocarbons were significantly elevated in patients treated dermally for different forms of dermatoses. The treatment period was for an average of 7 days using 1.5% - 40% coal tar preparations over a body surface area that ranged from 9 to 90%. Therefore some of the hydrocarbons present in coal tar may be absorbed through the skin. The highest levels absorbed depend largely on the body surface area treated and on the duration of exposure.

Many of the hydrocarbons will be subject to extensive metabolic transformation by both oxidation and conjugation. Drug-metabolizing enzymes (both in the skin and systemically) may be induced by coal tar application.

5.3 Preclinical safety data

Carcinogenesis and Mutagenesis

No long term studies have been conducted with the product formulations.

Coal tar contains certain chemicals that are mutagenic to microorganisms and mammalian cells in vitro. Topical and oral administration of high doses of coal tar to laboratory animals induces DNA adduct formation.

High dose administration of coal tar to laboratory animals is carcinogenic However, epidemiological evidence that includes prospective and retrospective studies in thousands of patients receiving coal tar therapy followed for more than 40 years do not suggest a potential increased risk of skin or systemic cancer.

Reproductive Toxicology

Coal tar is foetotoxic and teratogenic at maternally toxic doses following dermal application, oral administration, or inhalation.

6. Pharmaceutical particulars
6.1 List of excipients

Sodium lauryl sulphate solution

Ammonium lauryl sulphate solution

Lauramide DEA

Herbal Fragrance 41.423

Hydroxy Propyl Methyl Cellulose

Citric acid anhydrous

Guar Hydroxy Propyl Trimonium Chloride

Methyl Parahydroxybenzoate

Propyl Parahydroxybenzoate

Patent Blue V dye

Purified Water

6.2 Incompatibilities

None known

6.3 Shelf life

24 months

6.4 Special precautions for storage

None

6.5 Nature and contents of container

Alphosyl '2 in 1' shampoo is packaged in white opaque polypropylene bottles with wadded cap and pack sizes; 20, 100, 125, 250, 500 and 1000 ml

or

White opaque polypropylene bottles with a white polypropylene flip top cap and pack sizes 125 and 250ml.

It is also packaged in white opaque polypropylene tubes with screw cap and pack sizes 20, 100, 125, 250, 500 and 1000 ml.

It is also packaged in 10 ml PETP/PE/Foil Surlyn sachets.

6.6 Special precautions for disposal and other handling

None stated

7. Marketing authorisation holder

Omega Pharma Ltd.

1st Floor

32 Vauxhall Bridge Road

LONDON, SW1V 2SA

United Kingdom

8. Marketing authorisation number(s)

PL 02855/0063

9. Date of first authorisation/renewal of the authorisation

25/06/2008

10. Date of revision of the text

06/07/2015

Company contact details

Omega Pharma Ltd

Company image
Address

Omega Pharma Ltd, 1st Floor, 32 Vauxhall Bridge Road, London, SW1V 2SA, UK

Medical Information e-mail
Telephone

+44 (0)203 598 9603

Customer Care direct line

+44 (0)1748 828 860

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

coal tar extract

Legal categories

GSL - General Sales List

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue